One of the most interesting dynamics we see in early-stage MedTech companies is the relationship between the CEO and the doctor or researcher who originally invented the technology.

✅The Value of a Clinician-Inventor
On the surface, having a clinician as a co-founder is a huge asset. It signals credibility, if a doctor created it, it must be solving a real problem. They often bring a valuable network, access to clinical environments, and a strong platform to present findings at conferences. Plus, when the clinical study is investigator-initiated, the hospital can act as the Sponsor (in the ISO14155/GCP sense), saving the company significant time and money. What’s not to love?

🚨But There Are Challenges Too…
Doctors typically remain employed at academic or research hospitals. Their availability is limited, and critically, they don’t face the same downside risk as a CEO who’s all-in and racing against a runway. This difference in urgency can create friction.
There’s also the challenge of translation: what works in a highly resourced academic setting may not be feasible in a typical hospital. Adoption hurdles emerge when the product requires staff or workflows that are unrealistic outside the research bubble.

🎯Different Goals, Different Studies
And then there’s scope creep. Clinician-inventors often want to keep iterating or ensure the clinical study generates publishable, exciting data. But the CEO needs to finalize the product and design a study that gets regulatory approval fast. Sometimes that means prioritizing endpoints that are boring but necessary, or choosing shorter follow-up periods to accelerate time-to-market.

💡Business Insight: Alignment Is Everything
None of this means clinician involvement is a bad thing; in fact, it’s a huge part of what makes these ventures viable in the first place. But it
does require clear expectations and ongoing alignment.
These are conversations I regularly have with founders. Understanding this dynamic early can save time, money, and tension down the road.

📌 Do you recognize these challenges?
Share some of your experiences or ways to deal with these challanges.
If you’re a MedTech CEO navigating this space, happy to connect and chat informally.

To comment and share your thoughts join the conversation at LinkedIn!

Related posts:

Public Gatekeepers, Private Returns

The commercial incentives shaping EU medical device conformity assessment Key Messages The EU’s decentralized conformity assessment model relies on independent, mostly commercial notified bodies to

Read More »

Don’t hesitate to ask us your questions.

Drop an e-mail or contact us via LinkedIn

This website uses cookies to ensure you get the best experience on our website. If you want to get more information about this, please view our privacy policy page.